A PHASE-2, PROSPECTIVE, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND EFFICACY OF SOTATERCEPT (ACE-011) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) -ASSOCIATED MYELOFIBROSIS AND ANEMIA
MD Anderson Study Status
This phase II trial studies the side effects of and how well sotatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis or anemia. Sotatercept may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Anemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
For general questions about clinical trials:
Help us #endcancer
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.